Degroof Petercam Initiates Coverage, Signals Growing Investor Interest in Medincell
Event summary
- Degroof Petercam, a European investment bank, has initiated coverage of Medincell with a ‘Buy’ recommendation.
- Medincell is a commercial- and clinical-stage biopharmaceutical company focused on long-acting injectable treatments.
- The company’s risperidone LAI treatment, marketed as UZEDY® by Teva, received FDA approval in April 2023 and subsequent approval for Bipolar I Disorder in October 2025.
- Teva submitted an NDA for Olanzapine LAI to the U.S. FDA in December 2025, which was accepted on February 20, 2026.
The big picture
The initiation of coverage by Degroof Petercam suggests growing institutional interest in Medincell, particularly within the European market. This move validates the company’s strategy of expanding its presence in global capital markets and reflects the increasing demand for long-acting injectable therapies to improve patient adherence and treatment outcomes. The acceptance of Teva’s NDA for Olanzapine LAI further reinforces the potential of Medincell’s BEPO® technology and its ability to disrupt the antipsychotic market.
What we're watching
- Regulatory Headwinds
- The FDA’s review of Teva’s Olanzapine LAI NDA will be a key catalyst for Medincell’s stock performance, and any delays or rejections could negatively impact investor sentiment.
- Execution Risk
- Medincell’s ability to successfully advance its investigational pipeline and secure further licensing partnerships will be crucial for long-term growth and shareholder value.
- Market Dynamics
- How effectively Medincell can expand the adoption of its BEPO® technology beyond risperidone and olanzapine will determine its competitive positioning within the long-acting injectable market.
Related topics